Daiichi Sankyo Company, Limited (DSKYF)
OTCMKTS · Delayed Price · Currency is USD
25.61
+0.60 (2.40%)
Oct 9, 2025, 3:43 PM EDT
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 474.60B JPY in the quarter ending June 30, 2025, with 8.81% growth. This brings the company's revenue in the last twelve months to 1.92T, up 14.09% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1,924.68B JPY
Revenue Growth
+14.09%
P/S Ratio
3.78
Revenue / Employee
97.38M JPY
Employees
19,765
Market Cap
50.44B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
AMJ Global Technology | 39.00 |
Daiichi Sankyo Company News
- 3 days ago - AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha
- 3 days ago - DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02 - Benzinga
- 7 days ago - Daiichi Sankyo Establishes Third Research Institute in San Diego - Business Wire
- 8 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Advances in FDA Review - GuruFocus
- 14 days ago - Shares of Asian drugmakers drop after Trump threatens tariffs - Reuters
- 15 days ago - AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer - Seeking Alpha
- 20 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses On WCLC 2025 Highlights (Transcript) - Seeking Alpha